PROCEPT BioRobotics Announces Preliminary Fourth Quarter and Fiscal Year 2022 Revenue
09 1월 2023 - 10:00PM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a
surgical robotics company focused on advancing patient care by
developing transformative solutions in urology, today reported
preliminary unaudited revenue for the quarter and fiscal year ended
December 31, 2022.
Preliminary, Unaudited Revenue Highlights:
- Total revenue for the fourth quarter of 2022 is expected to be
in the range of $23.6 million to $23.8 million, compared to $10.1
million in the prior year period
- Total U.S. revenue of $21.6 million to $21.8 million for the
fourth quarter of 2022
- U.S. system sales of 28 robots, resulting in total U.S. system
revenue of approximately $10.4 million to $10.5 million for the
fourth quarter of 2022
- Total U.S. Handpiece and other consumables revenue of
approximately $10.2 million to $10.4 million for the fourth quarter
of 2022
- Total international revenue of approximately $2.0 million for
the fourth quarter of 2022
- Fiscal year 2022 revenue is expected to be approximately $74.8
million to $75.0 million, representing growth of approximately 117%
compared to the prior year period
The Company plans to report financial results for the fourth
quarter and fiscal year 2022 after market close on Tuesday,
February 28, 2023. The Company’s management will host a
corresponding conference call beginning at 1:30 p.m. Pacific Time /
4:30 p.m. Eastern Time. The preliminary results included in this
press release are unaudited and remain subject to adjustment.
Investors interested in listening to the conference call may do
so by following one of the below links:
- Webcast link for interested listeners:
- https://edge.media-server.com/mmc/p/pbyn22v3
- Dial-in registration for sell-side research analysts:
-
https://register.vevent.com/register/BIac8fb5d0a7e245dd9f8c5ad7c0b22c2e
Live audio of the webcast will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com. The webcasts will be available
for replay for at least 90 days after the event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 100 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Forward Looking StatementsThis release contains
forward‐looking statements within the meaning of federal securities
laws, including with respect to the Company’s preliminary revenue
results for the fourth quarter and full year 2022. You are
cautioned not to place undue reliance on these forward-looking
statements. Forward-looking statements are only predictions based
on our current expectations, estimates, and assumptions, valid only
as of the date they are made, and subject to risks and
uncertainties, some of which we are not currently aware.
Forward-looking statements may include statements regarding
financial guidance, market opportunity and penetration, the
Company’s possible or assumed future results of operations,
including descriptions of the Company’s revenues, gross margin,
profitability, operating expenses, installed base growth,
commercial momentum, reimbursement coverage, overall business
strategy, or information regarding the impact of the COVID-19
pandemic and other global events on the Company and its operations.
Forward‐looking statements should not be read as a guarantee of
future performance or results and may not necessarily be accurate
indications of the times at, or by, which such performance or
results will be achieved. These forward‐looking statements are
based on the Company’s current expectations and inherently involve
significant risks and uncertainties. Actual results and the timing
of events could differ materially from those anticipated in such
forward‐looking statements as a result of these risks and
uncertainties. These risks and uncertainties are described more
fully in the section titled “Risk Factors” in the Company’s filings
with the Securities and Exchange Commission (the “SEC”), including
the Company’s annual report on Form 10-K filed with the SEC on
March 22, 2022. PROCEPT BioRobotics does not undertake any
obligation to update forward‐looking statements and expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward‐looking statements contained
herein. These forward-looking statements should not be relied upon
as representing PROCEPT BioRobotics’ views as of any date
subsequent to the date of this press release.
Important Safety
Information
All surgical treatments have inherent and associated side
effects. For a list of potential side effects
visithttps://aquablation.com/safety-information/
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024